Difference between revisions of "Elmer 2017 US Patent"
From Bioblast
Tag: Reverted |
Tag: Manual revert |
||
| Line 17: | Line 17: | ||
|pathways=S, ROX | |pathways=S, ROX | ||
|instruments=Oxygraph-2k | |instruments=Oxygraph-2k | ||
|additional=Labels, | |additional=Labels, PBMCs | ||
}} | }} | ||
Latest revision as of 14:36, 5 July 2023
| Elmer E, Hansson MJ, Ehinger JK, Piel S, Moss S (2017) Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex I-related impairment of mitochondrial oxidative phosphorylation. US Patent US20170100359 A1. |
Elmer E, Hansson MJ, Ehinger JK, Piel S, Moss S (2017) US Patent
Abstract: The present invention relates to a succinate prodrug for use in the treatment or prevention of lactic acidosis.
• Bioblast editor: Kandolf G • O2k-Network Lab: SE Lund Elmer E
Labels: MiParea: Respiration, Pharmacology;toxicology
Organism: Human
Tissue;cell: Heart, Blood cells, Fibroblast, Macrophage-derived, Platelet
Preparation: Intact cells
Coupling state: LEAK, ROUTINE, OXPHOS, ET
Pathway: S, ROX
HRR: Oxygraph-2k
Labels, PBMCs
